Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Regeneron Pharmaceuticals, Inc. (REGN : NSDQ)
 
 • Company Description   
Regeneron is a biotechnology company focused on the discovery, development and commercialization of treatments targeting serious medical conditions. The company's portfolio boasts nine marketed drugs - Eylea, Dupixent, Praluent, Kevzara, Libtayo, Evkeeza, Inmazeb Arcalyst and Zaltrap. The company also developed an antibody cocktail for COVID-19, REGEN-COV. REGEN-COV is a cocktail of two monoclonal antibodies and was designed specifically to block the infectivity of SARS-CoV-2, the virus that causes COVID-19. Regeneron has a collaboration agreement with Roche for the same. While Regeneron has co-developed Eylea with Bayer's HealthCare unit, Praluent was co-developed with Sanofi. Regeneron collaborated with Bayer for the joint development and commercialization of co-formulated combinations of Eylea, rinucumab and nesvacumab for the treatment of ocular diseases or disorders outside the United States.

Number of Employees: 15,106

 
 • Price / Volume Information   
Yesterday's Closing Price: $527.78 Daily Weekly Monthly
20 Day Moving Average: 1,232,104 shares
Shares Outstanding: 107.96 (millions)
Market Capitalization: $56,982.03 (millions)
Beta: 0.43
52 Week High: $1,211.20
52 Week Low: $520.50
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -4.76% -9.75%
12 Week -21.65% -15.35%
Year To Date -25.91% -23.00%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
777 OLD SAW MILL RIVER ROAD
-
TARRYTOWN,NY 10591
USA
ph: 914-847-7000
fax: 914-347-2113
invest@regeneron.com http://www.regeneron.com
 
 • General Corporate Information   
Officers
Leonard S. Schleifer - Chief Executive Officer; Board co-Chair and Presid
George D. Yancopoulos - Board co-Chair; President and Chief Scientific Off
Christopher Fenimore - Executive Vice President; Finance and Chief Financ
Jason Pitofsky - Vice President; Controller
Bonnie L. Bassler - Director

Peer Information
Regeneron Pharmaceuticals, Inc. (CORR.)
Regeneron Pharmaceuticals, Inc. (RSPI)
Regeneron Pharmaceuticals, Inc. (CGXP)
Regeneron Pharmaceuticals, Inc. (BGEN)
Regeneron Pharmaceuticals, Inc. (GTBP)
Regeneron Pharmaceuticals, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 75886F107
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/07/25
Share - Related Items
Shares Outstanding: 107.96
Most Recent Split Date: (:1)
Beta: 0.43
Market Capitalization: $56,982.03 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.17%
Current Fiscal Quarter EPS Consensus Estimate: $6.63 Indicated Annual Dividend: $0.88
Current Fiscal Year EPS Consensus Estimate: $29.32 Payout Ratio: 0.02
Number of Estimates in the Fiscal Year Consensus: 9.00 Change In Payout Ratio: 0.02
Estmated Long-Term EPS Growth Rate: 8.76% Last Dividend Paid: 02/20/2025 - $0.88
Next EPS Report Date: 08/07/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: 18.00
Trailing 12 Months: 13.83
PEG Ratio: 2.06
Price Ratios
Price/Book: 1.94
Price/Cash Flow: 11.55
Price / Sales: 4.05
EPS Growth
vs. Year Ago Period: -19.32%
vs. Previous Quarter: -35.05%
Sales Growth
vs. Year Ago Period: -3.70%
vs. Previous Quarter: -20.07%
ROE
03/31/25 - 15.27
12/31/24 - 16.32
09/30/24 - 16.88
ROA
03/31/25 - 11.93
12/31/24 - 12.76
09/30/24 - 13.23
Current Ratio
03/31/25 - 4.93
12/31/24 - 4.73
09/30/24 - 5.28
Quick Ratio
03/31/25 - 4.03
12/31/24 - 3.95
09/30/24 - 4.46
Operating Margin
03/31/25 - 31.51
12/31/24 - 32.72
09/30/24 - 33.68
Net Margin
03/31/25 - 31.94
12/31/24 - 31.07
09/30/24 - 33.61
Pre-Tax Margin
03/31/25 - 35.38
12/31/24 - 33.66
09/30/24 - 35.89
Book Value
03/31/25 - 272.19
12/31/24 - 268.50
09/30/24 - 266.87
Inventory Turnover
03/31/25 - 0.66
12/31/24 - 0.67
09/30/24 - 0.69
Debt-to-Equity
03/31/25 - 0.09
12/31/24 - 0.09
09/30/24 - 0.09
Debt-to-Capital
03/31/25 - 8.43
12/31/24 - 8.44
09/30/24 - 8.44
 

Powered by Zacks Investment Research ©